Why ACADIA Pharmaceuticals Stock Is Back in Focus After Guidance Update

ACADIA Pharmaceuticals (ACAD) put its stock firmly on investors’ radar after raising 2026 earnings guidance and reporting second quarter results that showed higher revenue and net income compared with a year earlier.

The company now expects 2026 revenue between US$1.24b and US$1.30b, with NUPLAZID projected at US$760 million to US$790 million and DAYBUE at US$480 million to US$510 million. These updated figures illustrate how the market may reassess ACADIA Pharmaceuticals stock today.

The guidance update and June quarter results come after a period of strong momentum for ACADIA Pharmaceuticals, with a 90 day share price return of 32.6% and a 1 year total shareholder return of 15.56% that builds on a 5 year total shareholder return of 70.59%.

If this kind of earnings driven move has your attention, it could be a good moment to broaden your search to other neurology and rare disease players through 43 healthcare AI stocks

ACADIA Pharmaceuticals now appears to be a stronger business on paper after its guidance update and recent earnings. The real test is whether the current share price already reflects that improvement or still leaves room based on fundamentals.

Most Popular Narrative: 11.5% Undervalued

Compared with ACADIA Pharmaceuticals' last close at $29.41, the most followed narrative points to a fair value of $33.25, using a 7.25% discount rate and detailed earnings assumptions.

ACADIA's pipeline momentum with 9 disclosed programs and multiple late-stage clinical readouts expected by 2027 positions the company to significantly diversify its revenue streams, reducing risk from single-product dependence and providing potential for margin expansion as new products are launched.

Curious how this pipeline story ties into that higher fair value? The narrative relies on specific revenue growth, margin shifts, and a future earnings multiple that might surprise you.

Result: Fair Value of $33.25 (UNDERVALUED)

However, ACADIA Pharmaceuticals still faces key risks, including heavy reliance on NUPLAZID revenue and the high risk, high reward setup around upcoming remlifanserin trial results.

Next Steps

With ACADIA Pharmaceuticals showing both exciting prospects and clear pressure points, it makes sense to check the full picture for yourself and move quickly. To see how the balance of risks and rewards stacks up, take a closer look at the 4 key rewards and 1 important warning sign

Looking For More Investment Ideas Beyond ACADIA Pharmaceuticals?

If ACADIA Pharmaceuticals has sharpened your interest, do not stop here. Use the Simply Wall St screener to quickly spot other opportunities that could fit your approach.

• Target reliable growth potential by scanning screener containing 21 high quality undiscovered gems that combine strong fundamentals with relatively low market attention.
• Prioritise resilience by checking 83 resilient stocks with low risk scores that show lower overall risk profiles based on multiple factors.
• Focus on financial strength by reviewing the solid balance sheet and fundamentals stocks screener (48 results) and see which companies pair healthy balance sheets with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.